Evaluation of cancer immunotherapy using mini-tumor chips
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Rationale: Predicting tumor responses to adjuvant therapies can potentially help guide treatment decisions and improve patient survival.Currently, tumor pathology, histology, and molecular profiles are being integrated into personalized profiles to guide therapeutic decisions.However, it remains a grand challenge to evaluate tumor responses to immunotherapy for personalized medicine.Methods: We present a microfluidics-based mini-tumor chip approach to predict tumor responses to cancer immunotherapy in a preclinical model.By uniformly infusing dissociated tumor cells into isolated microfluidic well-arrays, 960 mini-tumors could be uniformly generated on-chip, with each well representing the ex vivo tumor niche that preserves the original tumor cell composition and dynamic cell-cell interactions and autocrine/paracrine cytokines.Results: By incorporating time-lapse live-cell imaging, our mini-tumor chip allows the investigation of dynamic immune-tumor interactions as well as their responses to cancer immunotherapy (e.g., anti-PD1 treatment) in parallel within 36 hours.Additionally, by establishing orthotopic breast tumor models with constitutive differential PD-L1 expression levels, we showed that the on-chip interrogation of the primary tumor's responses to anti-PD1 as early as 10 days post tumor inoculation could predict the in vivo tumors' responses to anti-PD1 at the endpoint of day 24.We also demonstrated the application of this mini-tumor chip to interrogate on-chip responses of primary tumor cells isolated from primary human breast and renal tumor tissues.Conclusions: Our approach provides a simple, quick-turnaround solution to measure tumor responses to cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408 · cited 1×
“2D reprogrammed tumor cell cultures or 3D organoids have demonstrated promising potential since they preserve tumor cell genetic makeup as well as a transcriptomic profile with high fidelity [20-26].”
BackgroundPatient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096 · cited 1×
“The viable cells can then be subject to various treatments for drug response prediction treatment selection [14-19].”
BackgroundA living biobank of breast cancer organoids captures disease heterogeneity
Sachs, N., de Ligt, J., Kopper, O., Gogola, E., Bounova, G., Weeber, F., Balgobind, A. V., Wind, K., Gracanin, A., Begthel, H., et al. (2018) · Cell · doi:10.1016/j.cell.2017.11.010 · Cited by 1,973 · cited 1×
“2D reprogrammed tumor cell cultures or 3D organoids have demonstrated promising potential since they preserve tumor cell genetic makeup as well as a transcriptomic profile with high fidelity [20-26].”
BackgroundDrost, J., & Clevers, H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0007-6 · Cited by 1,790 · cited 1×
“2D reprogrammed tumor cell cultures or 3D organoids have demonstrated promising potential since they preserve tumor cell genetic makeup as well as a transcriptomic profile with high fidelity [20-26].”
BackgroundOrganoid modeling of the tumor immune microenvironment
Neal, J. T., Li, X., Zhu, J., Giangarra, V., Grzeskowiak, C. L., Ju, J., Liu, I. H., Chiou, S.-H., Salahudeen, A. A., Smith, A. R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.11.021 · Cited by 1,556 · cited 1×
“Additionally, the microfluidic organotypic culture of tumor spheroids and air-liquid interface culture of multicellular tumor spheroids have been explored to successfully preserve TME components [19, 31-35].”
MethodSelf-citationDijkstra, K. K., Cattaneo, C. M., Weeber, F., Chalabi, M., van de Haar, J., Fanchi, L. F., Slagter, M., van der Velden, D. L., Kaing, S., Kelderman, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.009 · Cited by 1,135 · cited 1×
“An alternative is to subject already established organoids to immune cell infiltration, where T cells were added to the organoid culture to mimic peripheral immune cell infiltration and generate tumor-reactive T cells [27, 28].”
BackgroundEx Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
Jenkins, R. W., Aref, A. R., Lizotte, P. H., Ivanova, E., Stinson, S., Zhou, C. W., Bowden, M., Deng, J., Liu, H., Miao, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0833 · Cited by 594 · cited 1×
“Additionally, the microfluidic organotypic culture of tumor spheroids and air-liquid interface culture of multicellular tumor spheroids have been explored to successfully preserve TME components [19, 31-35].”
MethodAn ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer
Voabil, P., de Bruijn, M., Roelofsen, L. M., Hendriks, S. H., Brokamp, S., van den Braber, M., Broeks, A., Sanders, J., Herzig, P., Zippelius, A., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01398-3 · Cited by 380
Tumor-Vasculature-on-a-Chip for Investigating Nanoparticle Extravasation and Tumor Accumulation
Wang, H.-F., Ran, R., Liu, Y., Hui, Y., Zeng, B., Chen, D., Weitz, D. A., & Zhao, C.-X. (2018) · ACS Nano · doi:10.1021/acsnano.8b06846 · Cited by 161 · cited 1×
“Additionally, modeling tumor vasculature and structure on-chip could also facilitate understanding the TME and develop immune-oncology therapies [39, 40].”
BackgroundPatra, B., Chen, Y.-H., Peng, C.-C., Lin, S.-C., Lee, C.-H., & Tung, Y.-C. (2013) · Biomicrofluidics · doi:10.1063/1.4824480 · Cited by 109 · cited 1×
“The viable cells can then be subject to various treatments for drug response prediction treatment selection [14-19].”
BackgroundZhou, Z., Van der Jeught, K., Fang, Y., Yu, T., Li, Y., Ao, Z., Liu, S., Zhang, L., Yang, Y., Eyvani, H., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00805-x · Cited by 107 · cited 1×
“An alternative is to subject already established organoids to immune cell infiltration, where T cells were added to the organoid culture to mimic peripheral immune cell infiltration and generate tumor-reactive T cells [27, 28].”
BackgroundSelf-citation
Cited by
Understanding Immune‐Driven Brain Aging by Human Brain Organoid Microphysiological Analysis Platform
Ao, Z., Song, S., Tian, C., Cai, H., Li, X., Miao, Y., Wu, Z., Krzesniak, J., Ning, B., Gu, M., et al. (2022) · Advanced Science · doi:10.1002/advs.202200475 · Cited by 77
Self-citationBridging the gap between tumor-on-chip and clinics: a systematic review of 15 years of studies
Bouquerel, C., Dubrova, A., Hofer, I., Phan, D. T. T., Bernheim, M., Ladaigue, S., Cavaniol, C., Maddalo, D., Cabel, L., Mechta-Grigoriou, F., et al. (2023) · Lab on a Chip · doi:10.1039/d3lc00531c · Cited by 58
Organoid co‐culture models of the tumor microenvironment promote precision medicine
Gu, Z., Wu, Q., Shang, B., Zhang, K., & Zhang, W. (2024) · Cancer Innovation · doi:10.1002/cai2.101 · Cited by 47
Metadata
- Authors
- Ao, Z., Cai, H., Wu, Z., Hu, L., Li, X., Kaurich, C., Gu, M., Cheng, L., Lu, X., & Guo, F.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2022
- Volume
- 12
- Issue
- 8
- Pages
- 3628-3636
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W4285173503
- Cited by
- 52
- References
- 11
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.